0001062993-24-020566.txt : 20241212 0001062993-24-020566.hdr.sgml : 20241212 20241212200818 ACCESSION NUMBER: 0001062993-24-020566 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241210 FILED AS OF DATE: 20241212 DATE AS OF CHANGE: 20241212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gillheeney Gary S. CENTRAL INDEX KEY: 0001757373 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37906 FILM NUMBER: 241546474 MAIL ADDRESS: STREET 1: C/O ORGANOGENESIS INC. STREET 2: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Organogenesis Holdings Inc. CENTRAL INDEX KEY: 0001661181 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-575-0775 MAIL ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp. DATE OF NAME CHANGE: 20151215 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-12-10 0001661181 Organogenesis Holdings Inc. ORGO 0001757373 Gillheeney Gary S. C/O ORGANOGENESIS HOLDINGS INC. 85 DAN ROAD CANTON MA 02021 1 1 0 0 President and CEO 0 Class A Common Stock 2024-12-10 4 S 0 58525 3.64 D 3301201 D Class A Common Stock 2024-12-11 4 S 0 157448 3.64 D 3143753 D Class A Common Stock 2024-12-12 4 S 0 43359 3.55 D 3100394 D The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.4531 to $3.74, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.72, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.495 to $3.65, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. /s/ William R. Kolb, Attorney-in-Fact 2024-12-12